Incyte's Pemazyre Approved in Japan for Biliary Tract Cancer With FGFR2 Fusions

·

·

Incyte's Pemazyre Approved in Japan for Biliary Tract Cancer With FGFR2 Fusions

NEW YORK – The Japanese Ministry of Health, Labor, and Welfare (MHLW) has approved Incyte’s FGFR inhibitor pemigatinib (Pemazyre) for patients with FGFR2 fusion-positive unresectable biliary tract cancer that has progressed after chemotherapy.
See Original Article

Brazilian broker Loft is valued at $2.2 billion in new funding round

RIO DE JANEIRO (Reuters) – Brazilian digital real estate broker Loft has raised $425 million in its fourth funding round, which valued it at $2.2 billion, it said on Tuesday. Currently focused on selling and renting homes in Sao Paulo and Rio de Janeiro, Loft …
See Original Article

Add the area code: Mandatory 10-digit dialing beginning soon in St. Louis area

ST. LOUIS — If you need to dial a phone number in the St. Louis area, be prepared to press a few extra digits beginning this year. Mandatory 10-digit dialing will start to be phased in next month for people in 37 states and 83 area codes. This change includes …
See Original Article

Citi launches Zoom-Free Fridays, but there's a catch

“The blurring of lines between home and work and the relentlessness of the pandemic workday have taken a toll on our well-being,” Citi CEO Jane Fraser wrote in a Monday memo to all employees obtained by CNN Business. “It’s simply not sustainable.”.
See Original Article

Pfizer, after success in COVID-19, will go solo to develop other mRNA vaccines, CEO Bourla says

On the heels of its rapid development of a COVID-19 vaccine, Pfizer will attempt to use the same gene-based technology to advance other vaccines against a host of diseases, CEO Albert Bourla told the Wall Street Journal.
See Original Article



Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.